Caroline V.M. Verhagen
Netherlands Cancer Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Caroline V.M. Verhagen.
Radiotherapy and Oncology | 2015
Caroline V.M. Verhagen; Rosemarie de Haan; Floor Hageman; Tim P.D. Oostendorp; Annalisa L.E. Carli; Mark J. O’Connor; Jos Jonkers; Marcel Verheij; Michiel W. M. van den Brekel; Conchita Vens
BACKGROUND AND PURPOSE The PARP inhibitor olaparib is currently tested in clinical phase 1 trials to define safe dose levels in combination with RT. However, certain clinically relevant insights are still lacking. Here we test, while comparing to single agent activity, the olaparib dose and genetic background dependence of olaparib-mediated radiosensitization. MATERIALS AND METHODS Long-term growth inhibition and clonogenic assays were used to assess radiosensitization in BRCA2-deficient and BRCA2-complemented cells and in a panel of human head and neck squamous cell carcinoma cell lines. RESULTS The extent of radiosensitization greatly depended on the olaparib dose, the radiation dose and the homologous recombination status of cells. Olaparib concentrations that resulted in radiosensitization prevented PAR induction by irradiation. Seven hours olaparib exposures were sufficient for radiosensitization. Importantly, the radiosensitizing effects can be observed at much lower olaparib doses than the single agent effects. CONCLUSION Extrapolation of these data to the clinic suggests that low olaparib doses are sufficient to cause radiosensitization, underlining the potential of the treatment. Here we show that drug doses achieving radiosensitization can greatly differ from those achieving single agent activities, an important consideration when developing combined radiotherapy strategies with novel targeted agents.
Oral Oncology | 2018
David M. Vossen; Caroline V.M. Verhagen; Marcel Verheij; Lodewyk F. A. Wessels; Conchita Vens; Michiel W. M. van den Brekel
OBJECTIVE Locally advanced oral squamous cell carcinoma (OSCC) shows lower locoregional control and disease specific survival rates than laryngeal and pharyngeal squamous cell carcinoma (L/P-SCC) after definitive chemoradiotherapy treatment. Despite clinical factors, this can point towards a different tumor biology that could impact chemoradiotherapy response rates. This prompted us to compare the mutational profiles of OSCC with L/P-SCC. METHODS We performed target capture DNA sequencing on 111 HPV-negative HNSCC samples (NKI dataset), 55 oral and 56 laryngeal/pharyngeal, and identified somatic point mutations and copy number aberrations. We next expanded our analysis with 276 OSCC and 134 L/P-SCC sample data from The Cancer Genome Atlas (TCGA dataset). We focused our analyses on genes that are frequently mutated in HNSCC. RESULTS The mutational profiles of OSCC and L/P-SCC showed many similarities. However, OSCC was significantly enriched for CASP8 (NKI: 15% vs 0%; TCGA: 17% vs 2%) and HRAS (TCGA: 10% vs 1%) mutations. LAMA2 (TCGA: 5% vs 19%) and NSD1 (TCGA: 7% vs 25%) mutations were enriched in L/P-SCC. Overall, we find that OSCC had fewer somatic point mutations and copy number aberrations than L/P-SCC. Interestingly, L/P-SCC scored higher in mutational and genomic scar signatures associated with homologous recombination DNA repair defects. CONCLUSION Despite showing a similar mutational profile, our comparative genomic analysis revealed distinctive features in OSCC and L/P-SCC. Some of these genes and cellular processes are likely to affect the cellular response to radiation or cisplatin. Genomic characterizations may guide or enable personalized treatment in the future.
Oncotarget | 2018
Caroline V.M. Verhagen; David M. Vossen; Kerstin Borgmann; Floor Hageman; Reidar Grénman; Manon Verwijs-Janssen; Lisanne Mout; Roel J.C. Kluin; Marja Nieuwland; Tesa Severson; Arno Velds; Ron M. Kerkhoven; Mark J. O’Connor; Martijn van der Heijden; Marie-Louise F. van Velthuysen; Marcel Verheij; Volkert B. Wreesmann; Lodewyk F. A. Wessels; Michiel W. M. van den Brekel; Conchita Vens
Mutations in Fanconi Anemia or Homologous Recombination (FA/HR) genes can cause DNA repair defects and could therefore impact cancer treatment response and patient outcome. Their functional impact and clinical relevance in head and neck squamous cell carcinoma (HNSCC) is unknown. We therefore questioned whether functional FA/HR defects occurred in HNSCC and whether they are associated with FA/HR variants. We assayed a panel of 29 patient-derived HNSCC cell lines and found that a considerable fraction is hypersensitive to the crosslinker Mitomycin C and PARP inhibitors, a functional measure of FA/HR defects. DNA sequencing showed that these hypersensitivities are associated with the presence of bi-allelic rare germline and somatic FA/HR gene variants. We next questioned whether such variants are associated with prognosis and treatment response in HNSCC patients. DNA sequencing of 77 advanced stage HNSCC tumors revealed a 19% incidence of such variants. Importantly, these variants were associated with a poor prognosis (p = 0.027; HR = 2.6, 1.1–6.0) but favorable response to high cumulative cisplatin dose. We show how an integrated in vitro functional repair and genomic analysis can improve the prognostic value of genetic biomarkers. We conclude that repair defects are marked and frequent in HNSCC and are associated with clinical outcome.
Radiotherapy and Oncology | 2015
R.J. de Haan; Caroline V.M. Verhagen; Floor Hageman; T. Oostendorp; A. Di Carli; M.J. O'Connor; Jos Jonkers; B. Van Triest; M.W.M. van den Brekel; Marcel Verheij; Conchita Vens
classes of CBVTUMOR were reported to the total CBVTUMOR to show volume variations in percentage. Results: Variations of median rCBV between M0 and M2 were different for two groups of patients: rCBV increased when initial rCBV was <1.0 (Group_rCBV_M0<1) and rCBV decreased when initial rCBV was >=1.0 (Group_rCBV_M0>1), this was statistically significant (p<0.013). Mapping of color-coded voxels between M0 and M2 provided additional spatial and quantitative information about tumor perfusion: Group_rCBV_M0>1 presented a significant decrease of High_CBVTUMOR volume (p=0.015) simultaneously with a significant increase of the Normal_CBVTUMOR volume (p=0.012) after treatment. Group_rCBV_M0<1 presented a significant decrease of Low_CBVTUMOR volume (p=0.035) after treatment and an increase of the Normal_ and High_CBVTUMOR volumes. Two examples of these CBVTUMOR volumes variations between M0 and M2 are illustrated for a patient of each group over their anatomical MRI, respectively Fig1A for a patient of Group_rCBV_M0>1 and Fig1B for a patient of Group_rCBV_M0<1.
Molecular Oncology | 2015
Philip C. Schouten; Anita Grigoriadis; Thomas Kuilman; Hasan Mirza; Johnathan Watkins; Saskia A. Cooke; Ewald van Dyk; Tesa Severson; Oscar M. Rueda; Marlous Hoogstraat; Caroline V.M. Verhagen; Rachael Natrajan; Suet-Feung Chin; Esther H. Lips; Janneke Kruizinga; Arno Velds; Marja Nieuwland; Ron M. Kerkhoven; Oscar Krijgsman; Conchita Vens; Daniel S. Peeper; Petra M. Nederlof; Carlos Caldas; Andrew Tutt; Lodewyk F. A. Wessels; Sabine C. Linn
Anticancer Research | 2015
Roel Henneman; Hester S. van Monsjou; Caroline V.M. Verhagen; Marie-Louise F. van Velthuysen; Natalja T. ter Haar; E. Michelle Osse; Marta Lopez-Yurda; Alfons J. M. Balm; Michiel W. M. van den Brekel
Radiotherapy and Oncology | 2018
David M. Vossen; Caroline V.M. Verhagen; Marcel Verheij; Lodewyk F. A. Wessels; Conchita Vens; M.W.M. van den Brekel
Radiotherapy and Oncology | 2017
P. Essers; Caroline V.M. Verhagen; M. Van der Heijden; M.W.M. van den Brekel; Harry Bartelink; Marcel Verheij; Conchita Vens
Radiotherapy and Oncology | 2016
Marcel Verheij; R.J. de Haan; B. Van Triest; Jan H. M. Schellens; M.W.M. van den Brekel; Caroline V.M. Verhagen; Conchita Vens
Radiotherapy and Oncology | 2014
Conchita Vens; Caroline V.M. Verhagen; David M. Vossen; Floor Hageman; Kerstin Borgmann; Reidar Grénman; Ron M. Kerkhoven; Marcel Verheij; Lodewyk F. A. Wessels; M.W.M. van den Brekel